Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

161. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial

Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial 22683226 2012 06 19 2012 09 20 2014 11 20 1474-4465 11 7 2012 Jul The Lancet. Neurology Lancet Neurol Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. 579-88 10.1016/S1474-4422(12)70105-9 (...) Additional options are needed for monotherapy treatment of adults newly diagnosed with partial epilepsy. This trial compares the efficacy and tolerability of once-daily zonisamide with twice-daily controlled-release carbamazepine monotherapy for such patients. In this phase 3, randomised, double-blind, parallel-group, non-inferiority trial, adults from 120 centres in Asia, Australia, and Europe, aged 18-75 years and newly diagnosed with partial epilepsy, were randomly assigned (in a 1:1 ratio, done

EvidenceUpdates2012

162. Melatonin as add-on treatment for epilepsy.

Melatonin as add-on treatment for epilepsy. BACKGROUND: Epilepsy is one of the most common chronic neurologic disorders. Despite the plethora of antiepileptic drugs (AEDs) currently available, 30% of patients continue having seizures. This group of patients requires a more aggressive treatment, since monotherapy, the first choice scheme, fails to control seizures. Nevertheless, polytherapy often results in a number of unwanted effects, including neurologic disturbances (somnolence, ataxia (...) , dizziness), psychiatric and behavioral symptoms, and metabolic alteration (osteoporosis, inducement or inhibition of hepatic enzymes, etc.). The need for better tolerated AEDs is even more urgent in this group of patients. Reports have suggested an antiepileptic role of melatonin with a good safety profile. OBJECTIVES: To assess the efficacy and tolerability of melatonin as add-on treatment for epilepsy. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialized Register (May 2012

Cochrane2012

163. Ketogenic diet and other dietary treatments for epilepsy.

Ketogenic diet and other dietary treatments for epilepsy. BACKGROUND: The ketogenic diet, being high in fat and low in carbohydrates, has been suggested to reduce seizure frequency. It is currently used mainly for children who continue to have seizures despite treatment with antiepileptic drugs. Recently there has been interest in less restrictive ketogenic diets including the Atkins diet and the use of these diets has extended into adult practice. OBJECTIVES: To review the evidence from (...) randomised controlled trials regarding the effects of ketogenic and similar diets. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialised Register (June 2011), the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 2 of 4), MEDLINE (1948 to May week 4, 2011) and EMBASE (1980 to March 2003). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. SELECTION CRITERIA: Studies of ketogenic diets

Cochrane2012

164. Deep brain stimulation for refractory epilepsy (IPG416)

Deep brain stimulation for refractory epilepsy (IPG416) Deep brain stimulation for refractory epilepsy | Guidance and guidelines | NICE Deep brain stimulation for refractory epilepsy Interventional procedures guidance [IPG416] Published date: January 2012 Share Save Guidance A09.1 Implantation of neurostimulator into brain Plus Y53.3 Approach to organ under computed tomography scan control And/or Y53.7 Approach to organ under magnetic resonance imaging control In addition an ICD-10 code from (...) category G40.- Epilepsy is assigned. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian

National Institute for Health and Clinical Excellence - Interventional Procedures2012

165. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison

The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison Martyn-St James M, Glanville J, McCool R, Duffy S, Cooper (...) J, Hugel P, Lane PW CRD summary This review concluded that retigabine provided similar risks and benefits, compared with the other selected anti-epileptic drugs, as additional therapy, for patients with partial-onset seizures, with or without secondary generalisation, but the limitations of the analyses should be considered. These conclusions appear to be reliable. Authors' objectives To evaluate the efficacy and tolerability of retigabine, compared with selected anti-epileptic drugs. Searching

DARE.2012

166. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium

Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium Simoens S, De Naeyer L, Dedeken P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of lacosamide, added to standard anti-epileptic drug therapy, for patients with refractory focal epilepsy. The authors concluded that the addition of lacosamide appeared to be cost-effective, for patients with difficult-to-treat epilepsy, in Belgium

NHS Economic Evaluation Database.2012

170. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial.

Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. 22396514 2012 03 07 2012 03 12 2017 02 20 1538-3598 307 9 2012 Mar 07 JAMA JAMA Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. 922-30 10.1001/jama.2012.220 Despite reported success, surgery for pharmacoresistant seizures is often seen as a last resort. Patients are typically referred for surgery after 20 years of seizures, often too late to avoid significant disability (...) and premature death. We sought to determine whether surgery soon after failure of 2 antiepileptic drug (AED) trials is superior to continued medical management in controlling seizures and improving quality of life (QOL). The Early Randomized Surgical Epilepsy Trial (ERSET) is a multicenter, controlled, parallel-group clinical trial performed at 16 US epilepsy surgery centers. The 38 participants (18 men and 20 women; aged ≥12 years) had mesial temporal lobe epilepsy (MTLE) and disabling seizues for no more

JAMA2012

171. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy

Responsive cortical stimulation for the treatment of medically intractable partial epilepsy 21917777 2011 09 28 2011 11 15 2014 07 30 1526-632X 77 13 2011 Sep 27 Neurology Neurology Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. 1295-304 10.1212/WNL.0b013e3182302056 This multicenter, double-blind, randomized controlled trial assessed the safety and effectiveness of responsive cortical stimulation as an adjunctive therapy for partial onset seizures (...) in adults with medically refractory epilepsy. A total of 191 adults with medically intractable partial epilepsy were implanted with a responsive neurostimulator connected to depth or subdural leads placed at 1 or 2 predetermined seizure foci. The neurostimulator was programmed to detect abnormal electrocorticographic activity. One month after implantation, subjects were randomized 1:1 to receive stimulation in response to detections (treatment) or to receive no stimulation (sham). Efficacy and safety

EvidenceUpdates2011

172. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study.

The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. BACKGROUND: Surgery is increasingly used as treatment for refractory focal epilepsy; however, few rigorous reports of long-term outcome exist. We did this study to identify long-term outcome of epilepsy surgery in adults by establishing patterns of seizure remission and relapse after surgery. METHODS: We report long-term outcome of surgery for epilepsy in 615 adults (497 anterior (...) awareness than did those with no SPS (2·4, 1·5-3·9). Relapse was less likely the longer a person was seizure free and, conversely, remission was less likely the longer seizures continued. In 18 (19%) of 93 people, late remission was associated with introduction of a previously untried antiepileptic drug. 104 of 365 (28%) seizure-free individuals had discontinued drugs at latest follow-up. INTERPRETATION: Neurosurgical treatment is appealing for selected people with refractory focal epilepsy. Our data

Lancet2011

173. Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy

Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy Widjaja E, Li B, Schinkel CD, Ritchie LP, Weaver J, Snead OC, Rutka JT, Coyte PC Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of epilepsy surgery in children with intractable epilepsy. The authors concluded that surgical treatment was cost-effective compared with medical therapy, but larger samples and longer follow-up were required

NHS Economic Evaluation Database.2011

174. [Vagus nerve stimulation for refractory epilepsy]

[Vagus nerve stimulation for refractory epilepsy] Estimulacion del nervio vago para la epilepsia refractaria [Vagus nerve stimulation for refractory epilepsy] Estimulacion del nervio vago para la epilepsia refractaria [Vagus nerve stimulation for refractory epilepsy] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Regueiro A, Alcaraz A, Valanzasca P, Elorriaga N, Romano M, Rojas J Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Regueiro A, Alcaraz A, Valanzasca P, Elorriaga N, Romano M, Rojas J. Estimulacion del nervio vago para la epilepsia refractaria. [Vagus nerve stimulation for refractory epilepsy] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de

Health Technology Assessment (HTA) Database.2011

175. [Usefulness of video EEG for the assessment of patients with refractory epilepsy]

[Usefulness of video EEG for the assessment of patients with refractory epilepsy] Utilidad del video EEG en la evaluacion de paciente con epilepsia refractaria [Usefulness of video EEG for the assessment of patients with refractory epilepsy] Utilidad del video EEG en la evaluacion de paciente con epilepsia refractaria [Usefulness of video EEG for the assessment of patients with refractory epilepsy] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Lopez A, Rey-Ares L, Bardach (...) of patients with refractory epilepsy] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No 220. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and issues related coverage policies for the use of Video EEG. Authors' conclusions In patients with refractory epilepsy who have previously been studied using the standard diagnostic tests, telemetry video electroencephalography (V-EEG) seems to be an adequate diagnostic test

Health Technology Assessment (HTA) Database.2011

177. Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics

Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics 21747586 2011 07 12 2011 07 14 2017 02 20 0971-6866 17 Suppl 1 2011 May Indian journal of human genetics Indian J Hum Genet Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics. S4-S11 10.4103/0971-6866.80351 Epilepsy is one of the most prevalent neurological disorders, afflicting approximately 50 million Indians. Owing (...) to affordability and easy availability, use of first-generation antiepileptic drugs (AEDs) is heavily encouraged for the treatment of epilepsy in resource-limited countries such as India. Although first-generation AEDs are at par with second-generation AEDs in terms of efficacy, adverse drug reactions (ADRs) are quite common with them. This could be attributed to the inferior pharmacokinetic parameters such as nonlinear metabolism, narrow therapeutic index and formation of toxic intermediates. In addition

Indian journal of human genetics2011 Full Text: Link to full Text with Trip Pro

178. Felbamate as an add-on therapy for refractory epilepsy.

Felbamate as an add-on therapy for refractory epilepsy. BACKGROUND: Epilepsy is a chronic and disabling neurologic disorder, affecting approximately one per cent of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available drugs. Felbamate is one of the second generation antiepileptic drugs and its effects as an add-on therapy to standard drugs are assessed in this review. OBJECTIVES: To evaluate the efficacy and tolerability of felbamate versus (...) placebo when used as an add-on treatment for people with refractory partial-onset epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group Specialized Register (6 December 2010), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 6 December 2010), and PubMed (6 December 2010). There were no language restrictions. We reviewed the reference lists of retrieved studies to search for additional reports of relevant studies. We also contacted the manufacturers

Cochrane2011

179. Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy.

Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy. BACKGROUND: Poor adherence to antiepileptic medications is associated with increased mortality and morbidity. In this review we focus on interventions designed to assist patients with adherence to antiepileptic medications. OBJECTIVES: To determine the effectiveness of interventions aimed at improving adherence to antiepileptic medications in adults and children with epilepsy. SEARCH STRATEGY: We (...) searched the Epilepsy Group's Specialised Register (24 June 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 2) and electronic databases: MEDLINE (OVID) (1950 to June 2010); EMBASE (OVID) (1980 to 2010 Week 24); CINAHL (1982 to June 2010) and PsycINFO (22 June 2010), and the reference lists of relevant articles. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of adherence-enhancing interventions aimed at patients with clinical

Cochrane2011

180. Intravenous immunoglobulins for epilepsy.

Intravenous immunoglobulins for epilepsy. BACKGROUND: Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum IgA level, lack of IgG subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may represent a valuable approach and its efficacy has important implications for epilepsy management. OBJECTIVES (...) : To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects, when used as monotherapy or as add-on treatment for people with epilepsy. SEARCH STRATEGY: We searched the Cochrane Epilepsy Group Specialized Register (14 June 2010), the Cochrane Central Register of Controlled Trials (Issue 2 of 4, The Cochrane Library, 2010), MEDLINE (1950 to June 2010), Web of Science (14 June 2010), Current Controlled Trials (11 June 2010), the National Research Register

Cochrane2011